Lung Function Improvements Tied to Better Asthma Control in Children

(MedPage Today) -- In the VOYAGE trial, dupilumab (Dupixent) significantly reduced asthma exacerbations and improved lung function and asthma control in children (ages 6 to 11 years) with uncontrolled, moderate-to-severe asthma, with an acceptable...
Source: MedPage Today Allergy - Category: Allergy & Immunology Source Type: news